Shilajit and Blood Thinners (Warfarin, Apixaban, Rivaroxaban)

Shilajit is a traditional herbo‑mineral natural substance whose main components are humic compounds (including fulvic and humic acids) and minerals. Modern analyses indicate that, depending on origin, Shilajit consists largely of humic substances, which are thought to contribute to many of its biological effects (6).

Blood thinners such as warfarin (vitamin K antagonist) and the direct oral anticoagulants apixaban and rivaroxaban act at different points in the coagulation cascade. All three are used to lower the risk of thrombotic events – but inappropriate combinations may increase the risk of bleeding. This article outlines how Shilajit could potentially interact with these medicines, how this risk might be assessed, and what you may wish to consider in everyday use.

How might Shilajit influence the effect of blood thinners?

Pharmacodynamic mechanism: additive anticoagulant‑like effect

Preclinical data suggest that humic substances may inhibit the activation of blood platelets. In a mouse model, humic acids reduced thrombus formation by lowering GPIIb/IIIa activation on platelets and P‑selectin levels in plasma – indicative of antiplatelet‑like properties (1). Such an effect could, in theory, add to the action of warfarin or DOACs and thereby increase the tendency to bleed.

Pharmacokinetic aspects: metabolism and transport

• Warfarin: The more potent S‑warfarin is mainly metabolised via CYP2C9; R‑warfarin via CYP1A2/3A4. Changes in these enzymes affect warfarin levels and thus the INR value (4). For Shilajit itself there are currently no robust human data indicating clinically relevant inhibition or induction of CYP enzymes. The main issue is therefore considered to be pharmacodynamic (see above).
• Apixaban: A substrate of P‑glycoprotein (P‑gp) and mainly metabolised via CYP3A4. Strong P‑gp/CYP3A4 inhibitors or inducers can alter drug levels and may favour bleeding or thrombosis (2, 3). Such modulation has not so far been demonstrated for Shilajit.
• Rivaroxaban: Also a substrate of P‑gp/BCRP and partly dependent on CYP3A4; strong combined inhibitors/inducers are considered problematic (3). Here too, there are no robust data showing that Shilajit affects these pathways.

Shilajit Capsules

✓ High-quality, natural Shilajit from the Himalayas

✓ With 50% fulvic acid & 12% humic acid

✓ 500 mg Shilajit extract per capsule

✓ Extract ratio 50:1 (equivalent to 25,000 mg Shilajit resin per capsule)

£18.00

ADD TO BASKET

View product

Clinical evidence: what is known?

Direct human studies on Shilajit in combination with warfarin, apixaban or rivaroxaban are not currently available. The best evidence so far comes from animal models, in which humic acids (components of Shilajit) reduced thrombus formation via inhibition of platelet activation (1). For DOACs and warfarin there are extensive reviews on drug–drug interactions – these mainly concern established P‑gp/CYP interactions with other medicinal products, not with Shilajit (2, 3, 4).

In addition, the composition of Shilajit products varies considerably; some analyses have reported fluctuating levels of trace elements and heavy metals. Quality control is therefore essential (5, 6).

Risk assessment

Severity: moderate to potentially high (especially with additional NSAID/aspirin use or pre‑existing bleeding risks). Likelihood: plausible (supported by preclinical data), but uncertain due to lack of human studies. For DOACs, strong P‑gp/CYP3A4 modulators should additionally be avoided where possible (2, 3).

Practical recommendations

1. Medical advice before use: Discuss the use of Shilajit with your doctor or pharmacist if you are taking warfarin, apixaban or rivaroxaban.
2. Warfarin: When starting or stopping Shilajit, have the INR checked after 3–5 days and again after 7–10 days; any dose adjustment should only be made by a doctor.
3. DOACs (apixaban/rivaroxaban): Watch for signs of bleeding (e.g. bruising, nose/gum bleeding, black or tarry stools). Avoid additional NSAIDs/aspirin without medical advice (3).
4. Timing: Taking Shilajit and an anticoagulant at different times of day does not prevent a pharmacodynamic interaction. Spacing doses may, at most, help to minimise any theoretical absorption issues.
5. Product quality: Use only tested, purified Shilajit products with a certificate of analysis; low‑quality products may contain variable levels of constituents or heavy metals (5, 6).
6. Consider alternatives: If your focus is on energy, recovery or stress resilience, discuss non‑pharmacological options (sleep, physical activity, diet) and, where appropriate, other low‑interaction approaches with your doctor.

Further information

For more background on Shilajit, see our articles: Shilajit: Effects, Shilajit: Interactions and Shilajit: Side Effects.

Conclusion

The most likely interaction between Shilajit and blood thinners is considered to be pharmacodynamic: antiplatelet‑like effects could contribute to an increased tendency to bleed. For warfarin, CYP‑dependent influences are in principle important; for apixaban and rivaroxaban, P‑gp/CYP3A4 play a role – but for Shilajit itself such pharmacokinetic effects are currently not documented. Until robust human data are available, it is advisable to seek medical advice, to monitor INR closely when using warfarin, and to watch for signs of bleeding with DOACs. Choosing quality‑tested products is essential.

Medical disclaimer

Important notice: This information does not replace professional medical advice. Always consult your doctor or pharmacist before taking Shilajit together with [medicine]. Every individual may respond differently to food supplements and medicines.